Glucocorticoids in pregnancy: A master-switch for fetal maturation
Clicks: 1
ID: 314749
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #217 of 220 articles by views in endocrine reviews
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 220 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The prepartum surge in plasma glucocorticoids is a critical signal for fetal organ maturation, facilitating the transition from fetal reliance on the placenta for functions including respiration, nutrition, and waste removal to newborn use of their own physiological systems. The fetal glucocorticoid surge is conserved across mammalian species, but mechanisms driving the surge differ. Preterm birth interrupts fetal maturation because babies are born before the rise in endogenous glucocorticoids occurs, placing the newborn at greater risk of morbidity and mortality. In particular, lung immaturity increases risk of short-term and long-term respiratory disease. Antenatal corticosteroids (ACS) are routinely administered to women at risk of preterm birth to mimic the missed maturational signal of elevated glucocorticoids. Consequently, ACS improve neonatal survival and respiratory outcomes. Clinical guidelines universally recommend ACS use, but recommended regimens, gestational age limits, and use in settings of pre-existing maternal conditions vary. Importantly, preterm infants have variable responsiveness to ACS treatment, and do not benefit equally. While male fetal sex and fetal growth restriction may be associated with lower ACS responsiveness, there is limited understanding of underlying factors. Emerging evidence points to differential glucocorticoid receptor isoform expression and elevated pre-treatment plasma cortisol concentrations as potential contributors to variable ACS response. Improved insight into underlying mechanisms is crucial for identifying responsive subgroups and optimising ACS treatment beyond the current one-size-fits-all approach to enhance health outcomes for preterm infants.
| Reference Key |
openalex_W7162193162
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Yoshi Tan, Michael J. Stark, Vicki L. Clifton, Michael D Wiese, Janna L Morrison, Kathryn L. Gatford |
| Journal | endocrine reviews |
| Year | 2026 |
| DOI |
10.1210/endrev/bnag015
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.